Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04995107
Other study ID # 2021-047-KY-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 20, 2021
Est. completion date June 30, 2023

Study information

Verified date December 2021
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact Shudan Yu, master
Phone 15011460149
Email miaomiao101@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators plan to conduct the randomized controlled trial to evaluate the effectiveness of electro-press needle (EPN), a novel acupuncture needle combining shallow and gentle insertion with transdermal electrical stimulation, on menopause-associated hot flash in comparison with waiting-list group among women during menopausal transition and postmenopausal periods.


Description:

As the most common type of menopause-associated symptoms, hot flashes affect up to 85% of women aging between 40 and 65 years . In China, women suffer from hot flushes as long as 4 to 5 years on average, some of whom may bear the symptoms for 12 years.Hormone replacement therapy (HRT) is generally recommended to relieve menopause-associated hot flashes.However, long-term usage of HRT may increase the incidence of endometrial, breast and ovarian cancer, thrombosis and strokes.Results of previous studies indicated that acupuncture might help to relieve the symptoms.There is insufficient evidence supporting its effectiveness for relieving the hot flash symptom.


Recruitment information / eligibility

Status Recruiting
Enrollment 122
Est. completion date June 30, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: 1. Aged between 40-60 years old; 2. Scoring 14 points or more in at least one day during the one-week baseline assessment, or having an average of = 7 moderate or severe heating per 24 hours recorded in HF Dairy ; 3. Fulfilling either condition mentioned below: 1. The last menstrual period was more than 12 months ago (including 12 months); 2. In the late menopausal transition, and has amenorrhea for more than 60 days; 3. FSH=25IU, and has vasomotor symptoms of HF, sweating, insomnia, migraine, or restlessness, etc. 4. Volunteer to participate in this study and sign the informed consent. Exclusion Criteria: 1. Usage of HRT via transdermal administration in the previous one month, or via oral or intrauterine administration in the previous two months; usage of phytoestrogens therapy, transvaginal estrogen administration, or estrogen or progesterone injections in the previous three months; 2. Bilateral salpingo-oophorectomy; 3. Amenorrhea secondary to premature ovarian failure, ovarian cyst or tumor, thyroid disease, hyperprolactinemia, or Cushing's syndrome, etc.; 4. Accepted acupuncture or drugs to treat the symptoms of HF within the previous 3 months; 5. Received radiotherapy or chemotherapy before; 6. Coagulation dysfunction, or taking warfarin, heparin and other anticoagulant drugs at present; 7. Suffering from skin diseases, such as eczema, psoriasis, etc.; 8. Severe hepatic and renal insufficiency; 9. Uncontrolled hypertension, diabetes or thyroid disease; 10. Diabetic neuropathy and mental illness (including depression); 11. Being pregnant, breastfeeding or planning to be pregnant during the trial; 12. Regular usage of sedatives or anti-anxiety drugs; 13. Smoking for more than 5 years (at least twenty cigarettes a day on average) , or with the problem of alcohol abuse; 14. Installation of pacemakers; 15. Poor compliance.

Study Design


Intervention

Device:
Electro Press needle
Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (f44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of "dense intermittent wave", and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed).

Locations

Country Name City State
China Department of Acupuncture, Guang'anmen Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Participants'acceptability towards EPN Use the 3-point method to evaluate, unacceptable (0 points), acceptable (1 points), easy to accept (2 points), patients who cannot accept should be written the reason clearly.Only patients in electric press needle group will score. week 1 and 3,at the end of the first and ninth treatments
Other Participants' belief that EPN might help Participants in the EPN group will answer the following question before the first intervention: "Do you think acupuncture will be effective for treating the disease?"The participants can answer "Yes", "No", or "Unclear." Baseline assessmentweek 0
Other Participants' expectations of improvement to menopausal associated hot flashes Participants in the EPN group will answer the following question before the first intervention: "Do you think acupuncture will be effective for improving menopausal associated HF?" The participants can answer "Yes", "No", or "Unclear." Baseline assessment week 0
Other Safety assessment Adverse events and severe adverse events will be recorded in case report form, whether related to interventions or not. Through study completion
Primary the proportion of patients with a reduction of 50% or more on the mean 24-hour HF score from baseline The mean 24-hour HF score = (1 × number of mild HF + 2 × number of moderate HF + 3 × number of severe HF + 4 × number of very severe HF)/Number of days reported. week 6
Secondary The proportion of participants with a reduction of 50% or more on the mean 24-hour HF score from baseline The mean 24-hour HF score = (1 × number of mild HF + 2 × number of moderate HF + 3 × number of severe HF + 4 × number of very severe HF)/Number of days reported. week 3,18,30
Secondary The proportion of participants with a reduction of 50% or more in the mean 24-hour HF frequency from baseline The mean 24-hour HF frequency = total number of HF reported/Number of days reported. week 3,6,18,30
Secondary The proportion of patients with at least a 50% reduction in the mean 24-hour HF severity from baseline The mean 24-hour HF severity = (1 × number of mild HF + 2 × number of moderate HF + 3 × number of severe HF + 4 × number of very severe HF)/ Number of HF reported. week 3,6,18,30
Secondary The changes in the mean 24-h HF score from baseline The mean 24-hour HF score = (1 × number of mild HF + 2 × number of moderate HF + 3 × number of severe HF + 4 × number of very severe HF)/Number of days reported. week 3,6,18,30
Secondary The change of Menopause rating scale (MRS) score from baseline MRS is a common menopause specific subscale, including 11 items from psychological, somatic to urogenital, with 5 as minimal clinically important differences(MCID). week6, 18 and 30
Secondary TThe change of Menopause-Specific Quality of Life Questionnaire (MENQOL) score from baseline MENQOL consists of 29 items assessing four domains: VMS, physical symptoms, psychological symptoms, and urogenital/sexual symptoms,with 4 as minimal clinically important differences(MCID). week 6, 18 and 30
Secondary The proportion of participants reporting "significantly reduced" or "moderately reduced" based on Global Response Assessment (GRA) The response of participants to the treatments are divided into seven grades by GRA: significantly reduced, moderately reduced, slightly reduced, no change, slightly aggravated, moderately aggravated and significantly aggravated. The proportion of participants reporting "significantly reduced" or "moderately reduced" are recorded as the response rate of the overall efficacy. week 3 ,6, 18 and 30
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04587154 - Womens Study to Alleviate Vasomotor Symptoms N/A
Terminated NCT03642119 - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed NCT05061563 - A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults Phase 1
Completed NCT05419908 - Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes Phase 2
Completed NCT01281332 - Mechanical Device for the Relief of Hot Flashes Phase 2
Completed NCT01439945 - Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer Phase 2
Completed NCT00755417 - Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women Phase 3
Completed NCT00599456 - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women. N/A
Completed NCT01293695 - Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial N/A
Completed NCT00256685 - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Phase 3
Completed NCT00391417 - Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms Phase 3
Terminated NCT00244894 - Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer N/A
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Active, not recruiting NCT03580499 - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy N/A
Recruiting NCT06030388 - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women N/A
Recruiting NCT04418115 - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option? N/A
Recruiting NCT04861701 - Effect and Predictors for Hot Flush in Women Undergoing Static Stretching Exercise N/A
Active, not recruiting NCT05086705 - EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer N/A
Completed NCT05099159 - A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2) Phase 3
Completed NCT01140646 - Evaluation of SAMe for Hot Flashes Phase 2